Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Belda-Iniesta, C
220  Ergebnisse:
Personensuche X
?
1

Bevacizumab dose adjustment to improve clinical outcomes of..:

García-Romero, N. ; Palacín-Aliana, I. ; Madurga, R....
BMC Medicine.  18 (2020)  1 - p. , 2020
Link: https://doi.org/10.1186/..
 
?
2

OS10.6 Infigratinib (BGJ398) in patients with recurrent gli..:

Lassman, A B ; Sepúlveda-Sánchez, J M ; Cloughesy, T...
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii21-iii22 , 2019
Link: https://doi.org/10.1093/..
 
?
3

Polyethylene glycol improves current methods for circulatin..:

García-Romero, N. ; Madurga, R. ; Rackov, G....
Journal of Translational Medicine.  17 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
4

Integral nutritional approach to the care of cancer patient..:

Durán-Poveda, M. ; Jimenez-Fonseca, P. ; Sirvent-Ochando, M....
Clinical and Translational Oncology.  20 (2018)  9 - p. 1202-1211 , 2018
Link: https://doi.org/10.1007/..
 
?
5

A phase II study of feasibility and toxicity of bevacizumab..:

Sepúlveda, J. M. ; Belda-Iniesta, C. ; Gil-Gil, M....
Clinical and Translational Oncology.  17 (2015)  9 - p. 743-750 , 2015
Link: https://doi.org/10.1007/..
 
?
6

ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERS..:

Cloughesy, T. ; Finocchiaro, G. ; Belda-Iniesta, C....
Neuro-Oncology.  16 (2014)  suppl 5 - p. v81-v81 , 2014
Link: https://doi.org/10.1093/..
 
?
7

Lung adenocarcinoma in the era of targeted therapies: histo..:

Conde, E. ; Angulo, B. ; Izquierdo, E....
Clinical and Translational Oncology.  15 (2013)  7 - p. 503-508 , 2013
Link: https://doi.org/10.1007/..
 
?
8

Targeting Chk2 improves gastric cancer chemotherapy by impa..:

Gutiérrez-González, A. ; Belda-Iniesta, C. ; Bargiela-Iparraguirre, J....
Apoptosis.  18 (2012)  3 - p. 347-360 , 2012
Link: https://doi.org/10.1007/..
 
?
9

PCN40 Year to Year Budget Impact Analysis of Biological The..:

Martínez-Amores, B. ; Mezquita, L. ; Ibáñez de Cáceres, I....
Value in Health.  15 (2012)  7 - p. A416 , 2012
Link: https://doi.org/10.1016/..
 
?
10

PCN88 Cost-Effectiveness Analysis Per Life-Year Gained Base..:

Belda-Iniesta, C. ; Moreno, V. ; Martínez-Amores, B....
Value in Health.  15 (2012)  7 - p. A425 , 2012
Link: https://doi.org/10.1016/..
 
?
11

PCN71 Cost-Effectiveness Analysis of Cetuximab and Panitumu..:

Moreno, V. ; Martínez-Amores, B. ; Barriuso, J....
Value in Health.  15 (2012)  7 - p. A421-A422 , 2012
Link: https://doi.org/10.1016/..
 
?
12

199 IGFBP-3 promoter methylation activates the PI3K/Akt int..:

Cortés, M. ; de Miguel, M. ; Belda-Iniesta, C....
European Journal of Cancer Supplements.  8 (2010)  5 - p. 52 , 2010
Link: https://doi.org/10.1016/..
 
?
13

Checkpoint kinase 1 modulates sensitivity to cisplatin afte..:

Peralta-Sastre, A. ; Manguan-Garcia, C. ; de Luis, A....
The International Journal of Biochemistry & Cell Biology.  42 (2010)  2 - p. 318-328 , 2010
Link: https://doi.org/10.1016/..
 
?
14

485 Checkpoint kinase 1 modulates sensitivity to chemothera..:

Sanchez-Pérez, I. ; Peralta-Sastre, A. ; Manguan-Garcia, C....
European Journal of Cancer Supplements.  8 (2010)  5 - p. 124 , 2010
Link: https://doi.org/10.1016/..
 
?
15

Phase II study of a fixed dose-rate infusion of gemcitabine..:

Feliu, J. ; Borrega, P. ; León, A....
Cancer Chemotherapy and Pharmacology.  67 (2010)  1 - p. 215-221 , 2010
Link: https://doi.org/10.1007/..
 
1-15